We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Erba Mannheim Announces Availability of Validated Automated Protocols for ErbaLisa COVID-19 IgG and IgM ELISA Kits

By LabMedica International staff writers
Posted on 01 Sep 2020
Print article
Image: ErbaLisa COVID-19 IgM ELISA kit (Photo courtesy of Erba Mannheim)
Image: ErbaLisa COVID-19 IgM ELISA kit (Photo courtesy of Erba Mannheim)
Erba Mannheim (London, England) has announced availability of validated automated protocols for its range of ErbaLisa COVID-19 IgG and IgM ELISA kits in order to improve global availability of high-quality testing methods for SARS-CoV-2.

The ready-to-use ErbaLisa COVID-19 IgG and IgM ELISA kits allow for the qualitative and semi-quantitative detection of IgG/M antibodies to SARS-CoV-2 in human serum. Erba's solid phase assays use proven technology, and total incubation time is 50 minutes at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results. With full CE certification, the reliable and automation-friendly COVID-19 ELISA kits are now available through Erba's global distribution network, including in the US.

Optimized protocols for popular instruments manufactured by Dynex, Stratec, Awareness, and Delta Biologicals are now available, as well as for Erba's own analyzers including the ELAN 30s microstrip processor. Such protocols will help meet or exceed manual performance characteristics and start reporting clinical results faster and with more confidence.
"With more than one million ELISA COVID-19 tests already issued, we are confident this development will help labs adopt our high quality and high value tests more quickly," said Nikhil Vazirani, MD of Erba Mannheim.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: BIOTIA-ID is an NGS platform that accurately and sensitively diagnoses infectious disease-causing pathogens (Photo courtesy of Adobe Stock)

New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics

With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions.... Read more
Sekisui Diagnostics UK Ltd.